Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Refractory and/or Resistant Herpes Simplex Virus Mucocutaneous Infections in Adult Transplantation and Cellular Therapy Patients: A Single-Center Experience.

Cureus·2026
Same author

Expert Panel Review and Practical Guidance on Biomarker Testing with Engineered Immune Effector Cells.

Transplantation and cellular therapy·2026
Same author

Day-30 IL1RL1, CXCL9 and REG3α are prognostic for survival after mismatched unrelated donor transplantation.

British journal of haematology·2026
Same author

Clinical Characteristics and Outcomes of Invasive Aspergillosis in Patients with Hematological Malignancies and Transplantation and Cellular Therapies in the Contemporary Era.

Mycopathologia·2026
Same author

Extracorporeal Photopheresis for Chronic Graft-Versus-Host Disease According to 2014 NIH Consensus Criteria.

Journal of clinical apheresis·2025
Same author

Erratum to 'Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome'[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9].

Transplantation and cellular therapy·2025
Same journal

Fibrocytes drive JAK2V617F-mutated myelofibrosis: pitavastatin reverses marrow fibrosis and anemia.

Blood·2026
Same journal

Identifying steroid-refractory aGVHD before it happens.

Blood·2026
Same journal

ELISA-negative HIT: antibody recognition and relevance.

Blood·2026
Same journal

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same journal

A bone to pick with ferric carboxymaltose.

Blood·2026
Same journal

A step toward streamlining HIT diagnosis.

Blood·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

Targeting neovascularization in GVHD.

Krishna V Komanduri1

  • 1University of Miami Sylvester Cancer Center.

Blood
|April 27, 2013
PubMed
Summary
This summary is machine-generated.

Neovascularization in graft-versus-host disease (GVHD) is controlled by av integrins and microRNA miR-100. This finding offers new insights into GVHD pathogenesis and potential therapeutic targets.

More Related Videos

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Experiment Videos

Last Updated: May 11, 2026

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR
06:06

Induction and Scoring of Graft-Versus-Host Disease in a Xenogeneic Murine Model and Quantification of Human T Cells in Mouse Tissues using Digital PCR

Published on: May 23, 2019

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease
08:05

Bone Marrow Transplantation Platform to Investigate the Role of Dendritic Cells in Graft-versus-Host Disease

Published on: March 17, 2020

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Area of Science:

  • Hematology
  • Immunology
  • Molecular Biology

Background:

  • Graft-versus-host disease (GVHD) is a serious complication following allogeneic stem cell transplantation.
  • Neovascularization plays a critical role in the inflammatory processes underlying GVHD.

Purpose of the Study:

  • To investigate the molecular mechanisms regulating neovascularization in GVHD.
  • To identify key regulators of angiogenesis in the context of GVHD.

Main Methods:

  • The study by Leonhardt et al utilized models of GVHD to examine the role of specific molecular factors.
  • Analysis involved assessing the expression and function of av integrins and miR-100 in GVHD pathogenesis.

Main Results:

  • av integrins were identified as crucial regulators of neovascularization during GVHD.
  • MicroRNA miR-100 was found to modulate these av integrin-dependent processes.
  • The interplay between av integrins and miR-100 significantly impacts GVHD progression.

Conclusions:

  • av integrins and miR-100 are key molecular players in GVHD-associated neovascularization.
  • Targeting these pathways may offer novel therapeutic strategies for managing GVHD.
  • Further research into these mechanisms could improve transplant outcomes.